Study of Durvalumab plus Tremelimumab as First-line Treatment in Chinese Patients with Unresectable Hepatocellular Carinoma

Trial Identifier: D419CR00026
Sponsor: AstraZeneca
NCTID:: NCT05557838
Start Date: February 2023
Primary Completion Date: March 2025
Study Completion Date: March 2025
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 211405
CN Beijing, CN, CN-100730
CN Beijing, CN, 100142
CN Beijing, CN, 100021
CN changsha, CN, 410005
CN Changsha, CN, 410013
CN Chengdu, CN, 610041
CN fuzhou, CN, 350011
CN Guangzhou, CN, 510060
CN Guangzhou, CN, 510100
CN Guangzhou, CN, 510515
CN GUANGZHOU, CN, 510260
CN Hangzhou, CN, 310022
CN Harbin, CN, 150081
CN Ji Nan, CN, 2501117
CN Nanjing, CN, 210009
CN Nanjing, CN, 210029
CN Nanjing, CN, 2100008
CN Ningbo, CN, 315010
CN Shanghai, CN, 200032
CN Shanghai, CN, 200040
CN Shenyang, CN, 110001
CN Tianjin, CN, 300060
CN Tianjin, CN, 300170
CN Tianjin, CN, 300000
CN Wenzhou, CN, 325000
CN Wuhan, CN, 430079
CN Wuhan, CN, 430022
CN xi'an, CN, 710038
CN Zhangjiagang, CN, 215699
CN Zhengzhou, CN, 450000
CN Zhengzhou, CN, 450008